NEW YORK and KISSING, Germany, Dec. 05, 2016 -- invendo medical GmbH, a leading developer and distributor of sterile, single-use and robotically-assisted endoscopy products in the field of gastroenterology and GI surgery, today announced it has received CE Mark for the invendoscope™ SC200, the world’s first sterile, single-use colonoscope.
“Our revolutionary technology uniquely addresses the significant challenges associated with the cleaning and disinfecting of traditional reusable endoscopes by providing an ergonomically advanced endoscope that offers both sterility and single use,” said Timo Hercegfi, Chief Executive Officer of invendo medical. “The CE Mark is a significant accomplishment for our company, which enables us to provide endoscopists in Europe with a more advanced technology to perform colonoscopies and a system that enhances patient safety over current devices.”
As part of the new invendoscopy™ E200 System, the invendoscope™ SC200 is a sterile and single-use colonoscope that eliminates the main challenge of gastrointestinal endoscopy: the complex reprocessing of endoscopes and therefore patients’ risk for cross-contamination.
Current infection control guidelines require that devices such as colonoscopes only be high-level disinfected, as these devices are not able to sustain the high-temperature heat of sterilization or the long process of gas sterilization in the longer term. Though disinfection eliminates most viable microorganisms, it does not remove all of them, creating opportunities for cross-contamination among patients. In fact, more healthcare-associated infection outbreaks have been linked to contaminated endoscopes than to any other medical device.
The invendoscope™ SC200 is a simple, safe and effective solution to clinical and hygienic challenges, ensuring that every patient has a personal endoscope. The device is always ready for physicians to use, and this advanced technology leads endoscopy ergonomics into the 21st century.
In addition to addressing an unmet need in GI endoscopy infection control, invendoscopy™ technology is robotically-assisted and ergonomically designed to offer gastroenterologists greater control and enhance physician comfort while performing procedures.
The invendoscope™ SC200 also received 510(k) clearance from the U.S. Food and Drug Administration earlier this year. The company anticipates market introduction in 2017.
About invendo medical
Based in Kissing (near Munich), Germany and New York, U.S.A. invendo medical is dedicated to sterile, single-use and robotically-assisted HD endoscopy products in the field of gastroenterology and GI surgery. The company has over the last years embedded several proprietary technologies into its first product, the sterile and single-use invendoscope™ SC200, and will introduce a full suite of other sterile and single-use GI endoscopes in the future.
MEDIA CONTACT: Amy Feldman Lazar Partners Ltd. 212-867-1779 [email protected]


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Britain Courts Anthropic Amid US Defense Department Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Apple Turns 50: From Garage Startup to AI Crossroads
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 



